Fibrogen is reeling from the worst case of data manipulation in years, but six weeks after the scandal broke, the drug maker still hasn’t explained why or how it happened, or identify the people ...

Alzheimer’s disease research has had a tumultuous year. First, patients finally got a new treatment when the FDA approved Biogen’s Aduhelm, setting off a chorus of criticism and challenges for the ...

Mortgage-pricing data has gone digital. But when does transparency turn into coordination? In early October 2025, mortgage-technology provider Optimal Blue and three major lenders were sued in a ...